SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Pfizer reports positive Phase 3 results for vitiligo drug LITFULO

Pfizer announced that its once-daily drug LITFULO (ritlecitinib) demonstrated significant improvements in facial and total body repigmentation compared to a placebo in two Phase 3 trials for nonsegmental vitiligo. The company plans to submit for regulatory approval in the US and EU.

PFE

Pfizer said two Phase 3 trials found that once-daily LITFULO (ritlecitinib) significantly improved facial and total body repigmentation versus placebo in nonsegmental vitiligo. The company said it plans global regulatory submissions, including to the FDA and EMA.

Related stories